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Abstract
Background: Hypertrophic scar was first described over 100 years ago; PubMed has more than 1,000 references on the
topic. Nevertheless prevention and treatment remains poor, because 1) there has been no validated animal model; 2)
human scar tissue, which is impossible to obtain in a controlled manner, has been the only source for study; 3) tissues
typically have been homogenized, mixing cell populations; and 4) gene-by-gene studies are incomplete.
Methodology/Principal Findings: We have assembled a system that overcomes these barriers and permits the study of
genome-wide gene expression in microanatomical locations, in shallow and deep partial-thickness wounds, and pigmented
and non-pigmented skin, using the Duroc(pigmented fibroproliferative)/Yorkshire(non-pigmented non-fibroproliferative)
porcine model. We used this system to obtain the differential transcriptome at 1, 2, 3, 12 and 20 weeks post wounding. It is
not clear when fibroproliferation begins, but it is fully developed in humans and the Duroc breed at 20 weeks. Therefore we
obtained the derivative functional genomics unique to 20 weeks post wounding. We also obtained long-term, forty-six
week follow-up with the model.
Conclusions/Significance: 1) The scars are still thick at forty-six weeks post wounding further validating the model. 2) The
differential transcriptome provides new insights into the fibroproliferative process as several genes thought fundamental to
fibroproliferation are absent and others differentially expressed are newly implicated. 3) The findings in the derivative
functional genomics support old concepts, which further validates the model, and suggests new avenues for reductionist
exploration. In the future, these findings will be searched for directed networks likely involved in cutaneous
fibroproliferation. These clues may lead to a better understanding of the systems biology of cutaneous fibroproliferation,
and ultimately prevention and treatment of hypertrophic scarring.
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Introduction
After deep partial-thickness injury to the skin, it is common for
patients to heal with fibroproliferative (hypertrophic) scarring.
Although the condition has been recognized at least since 1893 [1]
and studied in detail, there is still no effective prevention or
treatment. The family of fibroproliferative disorders includes
cirrhosis, idiopathic pulmonary fibrosis, myelofibrosis, atheroscle-
rosis, rheumatoid arthritis, postsurgical adhesions, corneal fibrosis,
Dupuytren’s disease and the three dermal variants, fibroprolifera-
tive scarring, keloid formation and scleroderma. Tredget reviewed
these dermal conditions in 1994 [2] and in 2009 [3], making it
clear that in the 15 years between reviews no real advances in
prevention or treatment occurred. Scarring is a topic of interest
not only to burn researchers; Broerse has reported that burn
survivors also rank it among the most undesirable outcomes to be
solved [4].
Progress is hindered by lack of understanding of the transcrip-
tomics, proteomics, and metabolomics (the systems biology) of
cutaneous fibroproliferation, which prevents directed research
towards prevention/treatment. There are several barriers.
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1) There has been no accepted and validated in vivo animal
model of fibroproliferation that permits detailed study
of the effects of shallow and deep partial-thickness wounds
in pigmented and non-pigmented skin, over time
[5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]. Few animals
produce fibroproliferative scar. Using shallow partial-
thickness wounds as the control is important to eliminate
the events of normotrophic healing and few models permit
the use of simultaneous shallow and deep partial-thickness
wounds. Comparing pigmented and non-pigmented skin is
important, as the prevalence of fibroproliferative scarring is
higher in pigmented skin; few models include pigmented
and non-pigmented skin. Studying the process over time is
important, as it is not known when the process begins and
few models permit time studies.
2) The historical lack of an accepted animal model of
cutaneous fibrosis means that human tissues have been the
only source for study. However, it is impossible to obtain
human tissue immediately and serially after injury or onset
of disease in a given patient. The majority of studies have
analyzed tissues obtained months or years after injury or
onset, long after early signaling has ceased, and in the case of
burns, with no control of depth of injury, i.e. superficial or
deep partial-thickness. Robson [21] has demonstrated that
time is an important variable in wound repair. Cole [22]
reported that relevant gene expression might be early and
transient. Early and serial study of the fibroproliferative
process is crucial, yet is not possible with human tissue.
3) Studied human fibroproliferative tissue has been minced
and homogenized. This destroys skin microanatomy and
mixes all cell populations. Since superficial partial-thickness
injury does not produce fibroproliferative scar, but deep
partial-thickness injury does [23,24,25,26], the two dermal
levels and the microanatomical locations of skin must be
kept intact and distinct, so that events unique to each may
be recognized and interactions identified.
4) The final reason we have failed to understand cutaneous
fibroproliferation is that the process is probably multifacto-
rial; gene-by-gene study is likely incomplete. Northern blot
analysis and in situ hybridization have been used to evaluate
gene expression, but these methods are time consuming and
detect only a few genes per assay. Thus, a systems biology,
genome wide, approach is needed.
We have assembled a system that overcomes these barriers. It
includes 1) a validated large animal, Duroc (pigmented, red,
fibroproliferative)/Yorkshire (non-pigmented, white, non-fibro-
proliferative) porcine in vivo model of cutaneous fibroproliferation
that enables the study of two significant variables simultaneously
over time, wound depth and skin pigmentation, making it unique
among fibrosis models [27,28,29,30,31,32,33,34] (confirmed by
Hart [35,36,37,38,39,40,41,42,43,44,45,46]), 2) laser capture
microdissection that enables the study of the microanatomical
locations of skin, thus avoiding homogenization of the entire
organ, and 3) annotation of the Affymetrix Porcine GeneChipH
enabling global profiling.
Using this system we have focused on one microanatomical
location, the deep cone/fat dome. The cones of skin (Fig. 1a) were
Figure 1. Cone/fat domes of the skin. Panel A is uninjured human skin. Two cones are schematically outlined and the deep cone/fat dome is
circled. Panel B is human hypertrophic scar. The cone/fat dome deep to the scar is circled. (reprinted with permission of John Wiley & Sons including
open access and a creative common license).
doi:10.1371/journal.pone.0019024.g001
Figure 2. Cone/fat dome outlined in uninjured Duroc skin. The
cone/fat dome structure is present in Duroc and Yorkshire skin
(reprinted with permission of John Wiley & Sons including open access
and a creative common license).
doi:10.1371/journal.pone.0019024.g002
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described by Shoemaker in 1905 [47] and again by Jackson in 1953
[48]. Matsumura [49,50] and Zhu [27] revisited the cones. The
deep cone structure including the fat dome is present on those body
parts where hypertrophic scarring occurs, i.e. the cheek, neck, chest,
abdomen, back, buttock, arm, forearm, dorsum hand, thigh, leg,
dorsum foot, helical rim and ear lobe. Conversely, deep cones/fat
domes are not present on those body parts where hypertrophic scar
does not occur, including the scalp, forehead, concha, eyelid, palm
and sole. The deep cones/fat domes are not present in the early
human fetus nor are they present on the rat and rabbit and these do
not form hypertrophic scar. On the other hand, pigskin does include
deep cones/fat domes (Fig. 2). This structure is present beneath
partial-thickness burns and human hypertrophic scar (Fig. 1b) and
with the deep matrix, is all that remains of the dermis after deep
partial-thickness injury; it warrants investigation as having a role in
the fibroproliferative process.
We herein report the differential transcriptome over time and
the functional genomics unique to Week 20 post wounding, from
the deep cones/fat domes in the Duroc/Yorkshire porcine model
of fibroproliferative scarring following shallow and deep partial-
thickness wounds.
Materials and Methods
Some aspects of this section were described and reported by
Zhu [34]. If previously reported, we briefly summarize here.
The Model
The experimental wounds were deep partial-thickness, leaving
the deep portion of the dermal matrix and the deep aspect of the
cones. The control wounds were shallow partial-thickness. The
Duroc pigmented breed forms thick, fibroproliferative scar and
was the experimental breed. The Yorkshire non-pigmented breed
heals without fibroproliferative scar and was the control breed.
Shallow and deep partial-thickness, Duroc and Yorkshire wounds
over time are shown in Figs. 3, 4, 5, 6. A typical thick Duroc scar
following a deep partial-thickness wound of 0.0450 is shown in
Fig. 7.
Animal Tissues
The Institutional Animal Care and Use Committee of the
University of Washington approved this study numbered 2322-04.
We obtained (Q-Bar Farm, Dayton, OR) 3 female Duroc and 3
female Yorkshire pigs, 6 weeks old, approximately 15 kg. At seven
weeks, ten ,565 cm tangential, partial-thickness wounds were
created on the back of each anesthetized pig with a PadgettH
dermatome (Integra LifeSciences Corporation, Plainsboro, NJ) set
to 0.0200, five shallow and five deep partial-thickness. One pass of
the dermatome is sufficient for the shallow wounds but two or
three passes are necessary to create the deep partial-thickness
wounds. Full-thickness wounds were NOT included. The deep
and shallow partial-thickness wounds were alternated on the
animals to avoid repeatedly placing one wound depth in the same
anatomic location. The wounds were allowed to heal without
application of topical agents or dressings. At 1, 2, 3, 12 and 20
weeks post-wounding, 164 cm surgical biopsies were collected
from one shallow and one deep wound on each pig. The biopsies
were obtained near the center of the wounds and each wound was
biopsied only once. Furthermore, we have now followed two
Durocs and one Yorkshire for forty-six weeks.
Figure 3. Shallow Duroc wound at time of wounding, 3 weeks and 20 weeks post wounding. Shallow Duroc wound at time of wounding
(Panel A) and three weeks (Panel B) and twenty weeks (Panel C) post wounding. The wound is healed at 3 weeks and at 20 weeks there is no
contraction or thickening and hair growth is full with minimal hyperpigmentation.
doi:10.1371/journal.pone.0019024.g003
Figure 4. Deep Duroc wound at time of wounding and 3, 20 and 46 weeks post wounding. Deep Duroc wound at time of wounding
(Panel A) and three (Panel B), twenty (Panel C) and forty-six weeks (Panel D) post wounding. The wound is not completely healed at 3 weeks and at 20
weeks there is contraction, thickening, no hair growth and hyperpigmentation. The contraction, thickening, absent hair and hyperpigmentation
remain or have progressed at 46 weeks.
doi:10.1371/journal.pone.0019024.g004
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Human Tissues
Over the past years we have collected 82 human hypertrophic
scar tissue samples. The University of Washington Human
Subjects Division approved this study numbered 95-1109-E07
and specifically waived the need for consent since these samples
were obtained during surgical reconstruction and would otherwise
have been discarded. Most of these were obtained years after
injury as surgical reconstruction is usually performed after
considerable time has passed. However, three of these human
scar samples were obtained 6.7 to 10.8 months after injury and,
therefore, are ‘‘early’’ hypertrophic scar as defined by Santucci
[51]. These samples were all raised, red and hard. Sample
demographics were Black 2, White 1; upper extremity 2, neck 1;
times since injury 6.7 months and 10.8 months; and patient ages
were 19 and 54. We used these to spot confirm the deep Duroc
expression obtained at Week 20 post wounding (as described
below).
Laser Capture Microdissection
The cones and fat domes were described previously and
reviewed in the Introduction. Tissue from the deep dermal cones/
fat domes was obtained by laser capture microdissection with the
ArcturusH AutoPix Laser Capture Microdissection System (Mo-
lecular Devices Corporation, Sunnyvale, CA) as previously
reported.
RNA Isolation and Amplification
RNA was extracted with the PicoPureTM Kit (Molecular
Devices Corporation, Sunnyvale, CA) and quality monitored with
the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa
Clara, CA), the Agilent RNA 6000 Pico chip, and Eukaryote Total
RNA Pico. The sample RNA and 500 pg control RNA were
amplified with two rounds using the RiboAmpTM HS Kit
(Molecular Devices Corporation, Sunnyvale, CA). The comple-
mentary RNA was transcribed and labeled with biotinylated UTP
and CTP with the Affymetrix IVT Labeling Kit (Affymetrix, Santa
Clara, CA, USA). The quality and quantity of labeled comple-
mentary RNA was evaluated spectrophotometrically and with the
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara,
CA).
Hybridization of the Affymetrix GeneChipsH
The porcine tissue RNA was analyzed using the Porcine
GeneChipH and the human tissue RNA using the Human
GeneChipH Human Genome U133 plus 2.0. Scanning was
performed with GeneChipH Scanner 3000 (Affymetrix, Santa
Clara, CA, USA). The quality of the hybridization and overall
chip performance was evaluated by visual inspection of the raw
scanned data and the quality control measures in the Affymetrix
*.RPT report file. Sixty porcine chips were processed (2 breeds * 3
pigs per breed * 2 wound depths * 5 time points) (GSE26095) and
three human chips (GSE26213).
Annotation of the Porcine GeneChipH and Identification
of the Human Orthologs
Affymetrix updates the annotation of the Porcine GenechipH
quarterly, but does not use all available porcine data and is
therefore incomplete. To improve this annotation, we used new
tools developed at Iowa State University. The heart of these tools
is the ANEXdb database containing an alignment (called the Iowa
Porcine Assembly) of ,1.6 million publically available porcine
sequences [52]. This alignment created 140,087 consensus
sequences and 103,888 singletons, annotated by BLAST analysis
to human and other species. We mapped all new annotations back
to the GeneChipH sequences through BLAST analysis. These
analyses have provided human orthologs to 16,753 (69%) of the
Figure 5. Shallow Yorkshire wound at time of wounding, 3 weeks and 20 weeks post wounding. Shallow Yorkshire wound at time of
wounding (Panel A) and three (Panel B), and twenty weeks (Panel C) post wounding. The wound is healed at 3 weeks and at 20 weeks there is no
contraction, thickening or hyperpigmentation and full hair growth.
doi:10.1371/journal.pone.0019024.g005
Figure 6. Deep Yorkshire wounds at time of wounding, 3 weeks and 20 weeks post wounding. Deep Yorkshire wound at time of
wounding (Panel A) and three (Panel B), and twenty weeks (Panel C) post wounding. The wound is healed at 3 weeks and at 20 weeks there is no
contraction, thickening or hyperpigmentation and full hair growth.
doi:10.1371/journal.pone.0019024.g006
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Porcine GeneChipH probesets. Since some probesets match to the
same gene, this translates to 10,732 genes.
Corroboration of the Microarray Data
Technical validation of microarray measurements of gene
expression was done with qRT-PCR and has been reported
[34]. However, we have now performed further qRT-PCR. We
selected ten genes at random from Week 3, for which the
microarray data of the three bioreplicates for Duroc and Yorkshire
were consistent. qRT-PCR was performed as previously described
with four technical replicates [34]. In each set of ten, three genes
were removed as the PCR-determined fold change was ,1.5, the
lower limit of detection with the ABI Prism 7900H sequence
detection system (Applied Biosystems, Scottsdale, AZ). The genes
studied are shown in Table 1 and the results in Fig. 8.
A second way to corroborate array data is to examine the
control probesets. The GeneChipH includes 188 control probesets.
We examined the expression of these controls in the transcrip-
tomes to identify false positives. None of the control probesets
indicated differential expression with mixed effects linear regres-
sion, indicating that the probability of true negatives becoming
false positives is small.
Data Reduction by Filtering
In accord with recommendations of Bourgon[53] and others we
applied nonspecific filters prior to statistical analysis.
1) Control Probesets: The control probesets were removed
from further analysis.
2) Affymetrix Present Absent Calls: Those probesets called
Absent on all chips were removed from further analysis.
3) Human Ortholog: If the probe set could not be annotated to
a human ortholog, it was eliminated from further analysis.
4) Copy Number Dependent Artifacts [54,55]: It is known that
RiboAmp HS yields linear amplification. Nevertheless it is
possible that some transcripts respond differently to
amplification depending upon copy number. To be sure
that all probesets selected for functional genomics evaluation
are not affected by copy number, we processed three porcine
RNA samples at various dilutions and hybridized the
GeneChipH with and without amplification. This clarified
which probesets are not affected by copy number; the others
were excluded from iterative further analysis. Those selected
were either Present in all three dilutions (PPP) or Absent in
all three (AAA).
5) Human Expression: The porcine and human genomes and
the derivative biology are clearly not identical. Therefore,
gene expression in the porcine model must be filtered to
match expression in human fibroproliferative scar to be
relevant. We used our human scar tissues to confirm the
Duroc expression. Since signals between species and
between chips cannot be compared, we used the Affymetrix
Present Absent calls to accomplish this after discussion with
Affymetrix Technical Support. The porcine sample compa-
rable to early human hypertrophic scar, as defined by
Santucci[51], is the deep Duroc wound at Week 20. We
retained those probes that were PPP or AAA in the human
tissue and in the deep Duroc, Week 20 wounds. (Probesets
that were A on all 60 chips were removed with filter #2.)
6) Duplicate Genes: For multiple probesets mapping to the
same gene, we retained the probeset with the maximum
median expression value.
The Porcine GeneChipH contains 24,125 probesets. Table 2
shows the numbers of probesets remaining after each filter was
sequentially applied.
Differential Transcriptomes
There are three independent variables in this system including
time, breed (pigment), and wound depth. In addition, the system
includes paired measures (shallow and deep partial-thickness
wounds on the same animals), and repeated measures (using the
same animals at each time point). To control for wound depth, we
calculated the log ratio of deep partial-thickness wound expres-
sion/shallow partial-thickness wound expression. We then studied
breed(pigment) differences of the log ratios over time with mixed
linear regression, which accommodates paired measures and
repeated measures. This is represented symbolically by D
timeDbreed(pigment) Ddepth. We also studied breed(pigment):
time interaction.
We used software R 2.9.2 [56], Bioconductor 2.10.1 [57,58], affy
1.20.2 [59], gcrma 2.14.1 [60], maanova 1.14.0 [61], and q-value
1.18.0 [62]. We normalized the sixty chips with the affy [59] package
and the gcrma [60] algorithm and performed the mixed effects linear
regression utilizing the maanova package [61], Fs testing, and 1000
permutations to identify differential expression. We used q-values
[62] to limit false discoveries with q#0.2 considered to be significant.
In addition, if the q-value for regression on breed(pigment) was
#0.2, we used the maanova package to determine the p-values for
the null hypothesis of no breed(pigment):depth differences at each
Figure 7. Duroc scar following a deep wound of 0.0450. The thick
scar is visible at five months following a deep Duroc wound.
doi:10.1371/journal.pone.0019024.g007
Table 1. Genes studied with qRT-PCR.
Duroc Yorkshire
1 ANGPTL2 ANGPTL2
2 CDH11 CASP3
3 CSNK2B CDH11
4 CTSK CTSK
5 GNAI2 GNAI2
6 IFI30 IFI30
7 OAZ2 MRPS11
doi:10.1371/journal.pone.0019024.t001
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time point and considered #0.1 to be significant. This identified
the time point(s) at which the differential expression on factor
breed(pigment) occurred.
Functional Genomics Unique to Week 20
It is unknown when the process of fibroproliferative healing begins,
clinically or in animal models. It is clear however, in both humans
and the Duroc breed that the process is underway at 20 weeks post
injury. We applied three functional genomics methodologies to the
differential transcriptomes from 1, 2, 3, 12 and 20 weeks and then
selected and report those functions, diseases, canonical pathways,
ontology terms and gene sets that are unique to Week 20. The three
functional genomic approaches included:
1) IngenuityH Functions, Diseases and Canonical Pathways Anal-
ysis: Functional analysis was done with IngenuityH Pathways
Analysis (IngenuityH Systems, www.ingenuity.com, Application
version 8.6, Content version 3003). Parameters were set to default
including all data sources and without species filter (analysis
finalized on 8/1/2010). Functions and diseases are reported if the
p-value,0.05 and the group contained five or more genes.
Canonical pathways are reported if the p-value,0.05.
2) Gene Ontology: GoMiner (discover.nci.nih.gov/gominer) [63]
was used to identify enriched or over-represented biological
processes, cellular components and molecular functions. The
parameters included 1) all data sources, 2) human, mouse and
rat organisms, 3) evidence codes including TAS, IDA, IMP,
IGI, IPI, ISS, and RCA, 4) p and FDR=0.1, and 5) 1000
randomizations (analysis finalized on 8/1/2010). GO terms
are reported if q#0.20. We also used GOstats version 2.14.0, a
package in the R/Bioconductor system [64] with the p-value
cutoff set to 0.01. Results of GO Terms with Total Genes$ 5
are reported. To ensure robust findings, we report terms found
by both applications.
Table 2. Number of probesets remaining after filters applied
sequentially.
Filter Probesets Remaining After Filter
Control probesets 23,935
All ‘‘Absent’’ 19,109
Human ortholog 13,728
Copy number 9,045
Human match 4,083
Duplicate filter 3,409
doi:10.1371/journal.pone.0019024.t002
Table 3. Number of probesets differentially expressed at
each time point.
Week
Number of genes
differentially
expressed
Over expressed
in Duroc tissue
Under expressed
in Duroc tissue 1-pi0
1 24 8 16 0.00
2 62 30 32 0.09
3 64 32 32 0.00
12 38 12 26 0.08
20 111 80 31 0.32
doi:10.1371/journal.pone.0019024.t003
Figure 8. Comparison of PCR and microarray fold changes. Microarray fold changes were verified with qRT-PCR. The PCR fold changes for the
genes listed in Table 1 in the Duroc breed (Panel A) are in substantial agreement with the microarray fold changes (Panel B). Similarly, the PCR fold
changes in the Yorkshire breed (Panel C) demonstrate substantial agreement with the microarray fold changes (Panel D).
doi:10.1371/journal.pone.0019024.g008
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3) Gene Set Analysis: We utilized Gene Set Enrichment
Analysis (GSEA(Broad)) [65,66,67] and database c2.all.v2.5.
symbols.gmt. Parameters were set to default except for
min= 5 and permutation type set to ‘‘gene set’’. Sets were
selected if FDR the q-value#0.20 (analysis finalized on 8/1/
2010). We also utilized GSA version 1.03, part of the R/
Bioconductor system (http://www-stat.stanford.edu/,tibs/
GSA) [68]. Parameters were set to default except for min= 5
and the same gene sets were utilized. We report sets identified
by both applications.
Table 4. IngenuityH functions unique to Week 20 selected if p,0.05 and the function included five or more differentially
expressed genes.
IngenuityH Function Function Annotation
Collagen Genes with Differential
Expression Unique to Week 20
Cardiovascular System
Development and Function
Angiogenesis, cardiovascular process of blood vessel, proliferation of endothelial cells 4A1
Cell Morphology Morphology of cells, morphology of eukaryotic cells, morphology of normal cells 15A1
Cell-To-Cell Signaling and
Interaction
Binding of cells, binding of tumor cell lines, signaling of cells
Cellular Development Developmental process of tumor cells, growth of breast cancer cell lines
Cellular Growth and Proliferation Growth of breast cancer cell lines, proliferation of endothelial cells 4A1
Cellular Movement Migration of cell lines, migration of endothelial cells, migration of normal cells,
migration of tumor cell lines
4A1
Hematological System
Development and Function
Coagulation of blood, coagulation of bodily fluid
Organ Development and
Morphology
Morphogenesis of organ
Organismal Development Angiogenesis 4A1
Organismal Functions Coagulation of blood, coagulation of bodily fluid
Protein Synthesis and Trafficking
and Molecular Transport
Localization of protein
Skeletal and Muscular System
Development and Function
Development of muscle 5A3
Tissue Development Development of muscle, development of tissue 5A3
doi:10.1371/journal.pone.0019024.t004
Table 5. IngenuityH diseases unique to Week 20 selected if p,0.05 and the function included five or more differentially expressed
genes.
IngenuityH Disease Disease Annotation
Collagen Genes with
Differential Expression
Unique to Week 20
Cancer Breast cancer, carcinoma in situ, colorectal cancer, ductal carcinoma, epithelial ovarian
cancer, mammary tumor, metastasis of eukaryotic cells, prostate cancer, prostatic carcinoma,
prostatic intraepithelial neoplasia, tumorigenesis of cell lines, tumorigenesis of eukaryotic cells
4A1, 15A1
Cardiovascular Disease Cardiovascular disorder, coronary artery disease 4A1, 15A1
Connective Tissue Disorders Arthritis, connective tissue disorder, rheumatoid arthritis 4A1, 15A1
Dermatological Diseases and
Conditions
Dermatological disorder 4A1, 15A1
Genetic Disorder Alzheimer’s disease, coronary artery disease, epithelial ovarian cancer, prostate cancer,
prostatic carcinoma, prostatic intraepithelial neoplasia
4A1, 15A1
Immunological Disease Autoimmune disease, immunological disorder, rheumatoid arthritis 4A1
Inflammatory Disease Arthritis, rheumatoid arthritis 4A1
Inflammatory Response Inflammation
Neurological Disease Alzheimer’s disease 4A1
Ophthalmic Disease Ophthalmic disorder
Psychological Disorders Psychological disorder
Skeletal and Muscular Disorders Arthritis, rheumatoid arthritis 4A1
doi:10.1371/journal.pone.0019024.t005
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Results
Differential Transcriptomes
1) Regression on Factor Breed(Pigment). Mixed effects
linear regression on the factor breed(pigment) was accomplished.
Selection of those genes for which q,0.2 and for which p,0.1 at
one or more time points, returned a differential transcriptome of
162 genes. This differential transcriptome is the core result of this
project and includes genes for which the difference between
shallow and deep partial-thickness wounds is different between
breeds over time. The genes are listed alphabetically in Table S1.
The number of genes differentially expressed at each time point is
shown in Table 3.
2) Regression on Breed(Pigment): Time Interaction. None
of the genes that were significant when regressed on breed(pigment)
revealed a breed:time interaction, indicating that there is no evidence
that the difference between breeds varies at the different time points.
Functional Genomics Unique to Week 20
We found the functions, diseases, canonical pathways, gene
ontology terms and gene sets unique to Week 20. Since collagen
must be involved in the process at some point, we noted the
presence of collagen genes with differential expression unique to
Week 20 in the tables described below.
The IngenuityH functions unique to Week 20 are summarized in
Table 4 and the IngenuityH diseases unique to Week 20 in Table 5;
the complete unabridged data is provided in Table S2. The
IngenuityH canonical pathways unique to Week 20 are shown in
Table 6. The GO terms unique to Week 20 found by both
GoMiner and GO stats are shown in Table 7.The gene sets unique
to Week 20 found by both GSA and GSEA are summarized in
Table 8. The entire data set is included in Table S3.
Duroc Scar Thickness At 46 Weeks Post Injury
Mean scar thickness in three deep Duroc wounds on each of two
Durocs at 46 weeks was 7.861.8 mm, compared to 6.361.5 mm,
previously obtained at Week 20, demonstrating that the scar had
not regressed, and was perhaps even increasing in thickness. With
this 46-week data and the data from all 14 Durocs and five
Yorkshires, schematic mean thickness by time for Duroc and
Yorkshire deep wounds is shown in Figs. 9 and 10. The Duroc
breed produces considerably more granulation tissue and scar than
the Yorkshire breed.
Discussion
Differential Transcriptome
The fundamental, core output of this project is the differential
transcriptome provided in Table S1. These are the genes that were
Table 6. IngenuityH canonical pathways unique to Week 20 selected if p,0.05.
IngenuityH Canonical Pathways p-value Molecules
Bile Acid Biosynthesis 0.039 ALDH2, ACAA1
Complement System 0.039 C1R, CFH
G Protein Signaling Mediated by Tubby 0.047 GNG11, MRAS
Human Embryonic Stem Cell Pluripotency 0.005 FZD4, FGFR1, MRAS, PDGFD, FZD7
PDGF Signaling 0.045 MRAS, CAV1, PDGFD
Riboflavin Metabolism 0.006 TYR, ENPP2
Glioblastoma Multiforme Signaling 0.042 FZD4, MRAS, PDGFD, FZD7
Ovarian Cancer Signaling 0.015 GJA1, FZD4, MRAS, FZD7
doi:10.1371/journal.pone.0019024.t006
Table 7. The GO terms unique to Week 20 found by both GoMiner and GOstats (GoMiner q,0.2; GOstats p,0.01 and five or more
genes in the term).
Biological Processes Molecules
Collagen Genes with Differential
Expression Unique to Week 20 p-value
GO:0001568 blood vessel
development
CAV1, CDH5, FGF18, FGFR1, GJA1, GJA4, LAMA4, MKL2,
PTPRM, SERPINF1, TEK
.000
GO:0001944 vasculature
development
CAV1, CDH5, FGF18, FGFR1, GJA1, GJA4, LAMA4, MKL2,
PTPRM, SERPINF1, TEK
.000
GO:0048514 blood vessel
morphogenesis
CAV1, FGF18, FGFR1, GJA1, MKL2, PTPRM, SERPINF1, TEK .007
Molecular Functions
GO:0001871 pattern binding CCDC80, CFH, COL5A3, ECM2, LAYN 5A3 .000
GO:0004857 enzyme inhibitor
activity
ANXA5, OAZ2, PPP1R2, PROS1, SERPINF1, TWIST1 .001
GO:0005539 glycosaminoglycan
binding
CCDC80, CFH, COL5A3, ECM2, LAYN 5A3 .001
GO:0030247 polysaccharide
binding
CCDC80, CFH, COL5A3, ECM2, LAYN 5A3 .002
doi:10.1371/journal.pone.0019024.t007
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differentially expressed controlling for wound depth and breed(-
pigment) over time. It is a reasonable assumption that the
transcriptional aspect of the systems biology of fibroproliferative
scarring is contained within this collection, to be teased out for
interrogation with traditional reductionist methods.
One immediate observation is that the types of collagen implicated
differs from our previous report[34], In that study we suggested that
collagens I, III, IV, V, VI, VII, XIV and XV were differentially
expressed, whereas here we report only collagens IV, V and XV. The
filters and statistical criteria in this manuscript are far more stringent
than in the previous manuscript and the probesets for types I, III, VI,
VII and XIV failed to pass. It is interesting that three of the ‘‘lesser’’
collagens did pass the more stringent criteria and may be the key to
the collagen disorder in fibroproliferative scarring.
A second immediate observation relates to genes involved in
cutaneous pigment. It is clinically quite clear that the incidence of
hypertrophic scarring increases with increasing skin pigmentation.
Four genes known to be involved in skin pigmentation were
differentially expressed including FZD4, FZD7, SLC24A5 and
TYR. Their potential involvement in fibroproliferative healing
warrants exploration.
A third observation is that the number of genes differentially
expressed at Week 20 and the values of 1-pi0 (see Table 3, pi0 is
an estimate of the proportion of non-differentially expressed genes)
suggest that there is surge of differential expression at this time
point. This has three possible explanations: 1) laboratory error or
chance, 2) simple progression and biological magnification of a
process that started much earlier, or 3) an event that began and
ballooned after Week 12. Given that the pi0 values for Weeks 1-12
are quite low, we favor explanation #3. This, if true, has
significant ramifications as it implies that the aberrant process
begins quite late. It would then be related to events of late wound
remodeling rather than early wound healing and a different set of
biological events would be suspect.
Table 8. The gene sets unique to Week 20 found by both GSA and GSEA selected if q,0.2 and five or more genes in the set.
Gene Sets Brief Set Explanation
Collagen Genes with
Differential Expression Unique
to Week 20
ADIP HUMAN DN Down-regulated in primary human adipocytes, versus preadipocytes
ADIPOGENESIS HMSC CLASS2 UP Up-regulated 1-14 days following the differentiation of human bone marrow
mesenchymal stem cells (hMSC) into adipocytes, versus untreated hMSC cells
(Class II)
APOPTOSIS Genes involved in apoptosis
HSA04510 FOCAL ADHESION Genes involved in focal adhesion 4A1, 5A3
HSA04512 ECM RECEPTOR INTERACTION Genes involved in ECM-receptor interaction 4A1, 5A3
HSA04664 FC EPSILON RI SIGNALING PATHWAY Genes involved in Fc epsilon RI signaling pathway
TGFBETA C1 UP Upregulated by TGF-beta treatment of skin fibroblasts, cluster 1
TGFBETA EARLY UP Upregulated by TGF-beta treatment of skin fibroblasts at 30 min (clusters 1-3)
doi:10.1371/journal.pone.0019024.t008
Figure 9. Schematic of time course of wound thickness in deep Duroc wounds. A thick granulation tissue layer is present from wounding to
approximately 12 weeks and the scar layer progressively thickens to 46 weeks.
doi:10.1371/journal.pone.0019024.g009
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Functional Genomics Unique to Week 20
Several immediate observations may also be made on the
functional genomic results unique to Week 20. First, the
IngenuityH functions, GO terms and gene sets found from the
expression data confirm and are confirmed by studies done long
ago with very different methodologies. Kischer implicated mast
cells in 1972 [69] and angiogenesis in 1982 [70]. Massague
reviewed the TGFß family in 1990 [71]. Wassermann reported
differential expression of apoptotic genes in 1998 [72]. Dabiri [73]
recently implicated focal adhesions. This agreement further
confirms the validity of the model.
Other observations/questions include: Inflammatory disease
(Table 5) and the inflammatory response (Table 5) appear in the
findings. Inflammation has long been known to be part of fibrosis
[74] but why are the genes involved differentially expressed at
Week 20 and not before?
Angiogenesis appeared in the findings (Table 4, 7). That
angiogenesis is involved is not surprising, and was implicated by
Kischer thirty-eight years ago [70]. But, as for inflammation, why
are the genes involved differential at Week 20 and not before?
The similarity to various cancers is evident (Table 5). That
wound healing shares events with cancer has also been known for
some time, but again why does the similarity appear at Week 20?
And might the similarity lead to control of fibroproliferative
healing?
Adipogenesis appears in the outcomes (Table 8) and adipose
tissue derived stem cells are increasingly a part of wound healing
studies. Are events in the fat dome driving the fibroproliferation?
And finally, does the similarity to autoimmune rheumatoid
arthritis appearing at Week 20 (Table 5) provide a clue to etiology?
These and many other questions will emerge from these early
functional genomic results. The transcriptome will now have to be
searched for ‘‘answers’’ to be interrogated in the laboratory.
Duroc Scar Thickness At 46 Weeks Post Injury
One of the challenges to this porcine model has been that the
scar may be thick at twenty weeks but has matured away by one
year, unlike human hypertrophic scar. The observation that the
porcine thick scar has not disappeared at Week 46 and, in fact,
may be thicker indicates that, as in humans, the porcine scar is
long-lived.
System Variance
This is a complex system and there are many sources of
variance.
1. Purity of the breed of the pigs: The producer verified the
animals as representing the breeds; we required that the pigs
also match the phenotypic requirements of the National Swine
Registry.
2. Variable wound depth and site of biopsy within the wound:
Creation of tangential wounds with a dermatome is not precise.
However, we have created . 200 such wounds and so have
considerable experience. The wounds were biopsied in the
center where depth is most uniform.
3. Pigs ‘‘snuffling’’ on wounds: The pigs were separated for 3–5
days post wounding.
4. Infection: With our open wound model, infection occurred in
only 1 of 20 pigs, 1 in ,200 wounds. This wound is not
included in this report.
5. RNA degradation: We have addressed this with the following:
1) time from excision to snap freeze, accomplished in ,10
minutes, 2) time for cryosection, accomplished in ,20 minutes,
and 3) time for laser capture microdissection, accomplished in
this fibrous tissue in,45 minutes, very analogous to Ryge [75].
In addition, King has demonstrated that the biological
variability is greater than the variance introduced here [76].
6. Multiple cell types in the laser microdissected tissues: This is by
design and of necessity, since at this point we do not know
which cell type(s) are involved in the process.
7. Dermatome wound model: This model, as described by
Silverstein [77,78], uses wounds created with a dermatome,
not thermal injury. However, it is well known to clinicians that
Figure 10. Schematic time course of wound thickness in deep Yorkshire wounds. The granulation tissue layer and the scar layer in the
Yorkshire breed are much thinner than in the Duroc breed.
doi:10.1371/journal.pone.0019024.g010
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deep donor sites and deep abrasions frequently develop
hypertrophic scars.
8. Genes not on the chip or not annotated: It is possible that the
genes involved in fibroproliferative healing are not on the
current AffymetrixH Porcine GeneChipH. However, the chip
contains approximately two thirds of the porcine genome, so is
likely to provide clues to the causes. Another possibility is that
the genes involved in cutaneous fibrosis are not annotated. We
kept the GeneChipH annotated with updated information.
9. False positives/negatives: We controlled false positives as described
and since we searched for expression patterns made up of several
genes, not individual genes, false negatives are unlikely.
Summary
Wynn has nicely reviewed and summarized the current
understanding of tissue fibrosis[74] from whom we quote:
Most chronic fibrotic disorders have in common a persistent irritant that
sustains the production of growth factors, proteolytic enzymes, angiogenic
factors and fibrogenic cytokines, which stimulate the deposition of
connective tissue elements that progressively remodel and destroy normal
tissue architecture.
The clues we here report may identify the ‘‘persistent irritant’’.
The differential transcriptome, refined by time span, wound depth
and pigment; the appearance of the ‘‘lesser’’ collagen genes (4, 5
and 15); the overlap of transcriptome and pigment genes; and the
related functions, diseases, canonical pathways, GO terms and
gene sets together may lead to a differential transcriptome-driven
hypothesis to explain and to treat the fibroproliferative condition.
Supporting Information
Table S1 Gene Sets Uniquely Significant at Week 20. Columns
4 and 5 are the regression p and q values. Columns 6–10 are the p-
values for each time point and whether the gene was differentially
over or under expressed in Duroc compared to Yorkshire. Empty
cells indicate that the weekly p-values did not achieve significance.
(XLS)
Table S2 Functions and Diseases Uniquely Significant at Week
20.
(XLS)
Table S3 Gene Sets Uniquely Significant at Week 20.
(XLS)
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